Drug intelligence / Profile preview

guanethidine

Development stage
Preclinical
Lead developer
Novartis
Modality
Small Molecules
Administration
Oral, Intravenous, Ophthalmic
01

Overview

Guanethidine is a peripherally acting antihypertensive agent used primarily for the management of moderate to severe hypertension. It works by inhibiting the release of norepinephrine from postganglionic sympathetic nerve terminals. Guanethidine is transported into sympathetic neurons via the norepinephrine transporter (NET), where it accumulates in storage vesicles and gradually depletes norepinephrine stores. This leads to reduced sympathetic tone and vasodilation, lowering blood pressure. The drug does not block catecholamine release from the adrenal medulla and does not produce parasympathetic blockade. Once widely used for resistant hypertension and hypertensive emergencies, its use has declined due to side effects and availability of newer agents; it is now withdrawn or unavailable in many countries but may still be licensed elsewhere[4][6][7]. It has also been used off-label for certain pain syndromes such as complex regional pain syndrome[4].

Brand names
Ismelin
Other names
(2-(hexahydro-1(2h)-azocinyl)ethyl)guanidine(2-(Octahydro-1-azocinyl)ethyl)guanidine2-(1-N,N-Heptamethyleneimino)ethylguanidine2-(1'-Azacyclooctyl)ethylguanidineAzocine, 1-(2-guanidinoethyl)octahydro-guanéthidineguanethidinumguanetidinaGuanidine, (2-(hexahydro-1(2H)-azocinyl)ethyl)-Heptamethylenimine, 1-(2-guanidinoethyl)-N-(2-perhydroazocin–1–ylethyl)guanidine
02

Targets

NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on guanethidine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on guanethidine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call